Current address for Dr. Williams: Biogen Idec, Cambridge, MA, USA.
Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone
Article first published online: 26 FEB 2013
Copyright © 2013 Movement Disorder Society
Volume 28, Issue 4, pages 490–497, April 2013
How to Cite
Graham, D. J., Williams, J. R., Hsueh, Y.-H., Calia, K., Levenson, M., Pinheiro, S. P., MaCurdy, T. E., Shih, D., Worrall, C. and Kelman, J. A. (2013), Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone. Mov. Disord., 28: 490–497. doi: 10.1002/mds.25351
Funding agencies: This study was funded by the Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) under an intra-agency agreement. The views expressed are the authors and not necessarily those of the CMS, the FDA, or the Department of Health and Human Services.
Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 8 APR 2013
- Article first published online: 26 FEB 2013
- Manuscript Accepted: 16 DEC 2012
- Manuscript Revised: 10 DEC 2012
- Manuscript Received: 19 OCT 2012
Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.